IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors), IKZF3 inhibitors(Zinc finger protein Aiolos inhibitors), Ubiquitin-protein ligases modulators

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [3]

Active Indication

Multiple MyelomaRefractory Multiple MyelomaRelapse multiple myeloma+ [3]

Inactive Indication-

Originator Organization

Celgene Corp.

Active Organization

Celgene Corp.

Bristol Myers Squibb Co.Ohio State University Comprehensive Cancer Center

+ [1]

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC32H30FN5O4

InChIKeyYTINZZFBHWSAGL-NDEPHWFRSA-N

CAS Registry2259648-80-9

Clinical Trials associated with Mezigdomide

NCT06627751

/ Not yet recruitingPhase 2IIT

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease [EMD]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.

Start Date01 Apr 2025

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

NCT06645678

/ RecruitingPhase 1/2IIT

Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/refractory Multiple Myeloma Patients

The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.

Start Date26 Nov 2024

Sponsor / Collaborator

Seoul National University Hospital

NCT06048250

/ RecruitingPhase 1IIT

A Phase 1 Study of Mezigdomide (CC-92480) and Dexamethasone Post Idecabtagene Vicleucel in Relapsed Multiple Myeloma

This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.

Start Date09 Apr 2024

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Mezigdomide

100 Translational Medicine associated with Mezigdomide

100 Patents (Medical) associated with Mezigdomide

Literatures (Medical) associated with Mezigdomide

17 Jan 2025·ACS Chemical Biology

Functional Characterization of Pathway Inhibitors for the Ubiquitin-Proteasome System (UPS) as Tool Compounds for CRBN and VHL-Mediated Targeted Protein Degradation

Article

Author: Müller, Susanne ; Menge, Amelie ; Knapp, Stefan ; Robers, Matthew B. ; Schwalm, Martin P. ; Elson, Lewis ; Greco, Francesco A.

Small molecule degraders such as PROteolysis TArgeting Chimeras (PROTACs) and molecular glues are new modalities for drug development and important tools for target validation. When appropriately optimized, both modalities lead to proteasomal degradation of the protein of interest (POI). Due to the complexity of the induced multistep degradation process, controls for degrader evaluation are critical and commonly used in the literature. However, comparative studies and evaluations of cellular potencies of these control compounds have not been published so far. Here, we investigated a diverse set of ubiquitin pathway inhibitors and evaluated their potency and utility within the CRBN and VHL-mediated degradation pathway. We used the HiBiT system to measure the level of target rescue after treatment with the control compounds. In addition, the cell health was assessed using a multiplexed high-content assay. These assays allowed us to determine nontoxic effective concentrations for control experiments and to perform rescue experiments in the absence of cellular toxicity.

01 Nov 2024·Clinical Lymphoma Myeloma & Leukemia

Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma

Review

Author: van Rhee, Frits ; Patel, Tanvi H ; Al Hadidi, Samer

Multiple Myeloma (MM) remains a challenging hematological malignancy despite significant advancements made during the past 2 decades. Outcomes have improved by incorporating immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies into treatment algorithms that include high dose chemotherapy and autologous hematopoietic stem cell transplantation. However, many patients may eventually relapse despite these innovations. Newer therapies targeting B-Cell Maturation Antigen (BCMA) offer promise for patients with relapsed or refractory disease. BCMA-targeted therapies carry notable side effects, necessitating vigilant monitoring and proactive infection prevention measures. They can also induce considerable immunosuppression, attributed to lower levels of immunoglobulins and increased susceptibility to infections. There is still a need for alternative treatment options with different mechanisms of action that can be easily administered and have a better safety profile. In addition, pomalidomide only overcomes lenalidomide refractoriness in a subset of patients. This review aims to explore 2 next-generation cereblon E3 ligase modulators (CELMoDs), Mezigdomide (CC92480), and Iberdomide (CC-220). We will discuss the biological aspects of these agents, including their mechanisms of action, efficacy, and toxicity profile, and provide a comprehensive review of current literature. Special attention will be paid to ongoing and future clinical trials that provide insights into the potential of these novel therapies in the management of MM.

01 Sep 2024·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives

Article

Author: Krönke, Jan ; Gütschow, Michael ; Garchitorena, Kathleen M ; Sievers, Johannes ; Figg, William D ; Lu, Feiteng ; Voget, Rabea ; Chau, Cindy H ; Ng, Yuen Lam Dora ; Steinebach, Christian

Introduction of fluorine into bioactive molecules has attracted much attention in drug development. For example, tetrafluorination of the phthalimide moiety of immunomodulatory drugs (IMiDs) has a strong beneficial effect on the ability to inhibit angiogenesis. The neomorphic activity of E3 ligase complexes is induced by the binding of IMiDs to cereblon. We investigated that a set of eight thalidomide analogs, comprising non- and tetrafluorinated counterparts, did not induce the degradation of neomorphic substrates (IKZF3, GSPT1, CK1α, SALL4). Hence, the antiangiogenic activity of fluorinated IMiDs was not triggered by neosubstrate degradation features. A fluorine scanning of non-traditional IMiDs of the benzamido glutarimide chemotype was performed. By measuring the endothelial cell tube formation, no angiogenesis inhibitors were identified, confirming the narrow structure-activity window of IMiD-induced antiangiogenesis.

News (Medical) associated with Mezigdomide

12 Feb 2025

·www.businesswire.com

Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to one of its lead programs, OPN-6602, for the treatment of multiple myeloma (MM). OPN-6602 is an oral, small molecule inhibitor of the E1A binding protein (EP300) and CREB-binding protein (CBP) currently being tested in a Phase 1 trial in patients with relapsed or refractory MM. Multiple myeloma is a rare and aggressive cancer of the plasma cells in the bone marrow that often leads to serious complications such as bone damage, kidney failure and immune suppression. The disease is typically diagnosed in older adults, with limited treatment options available for patients with relapsed or refractory disease. “We are pleased to have received ODD for OPN-6602 for the treatment of multiple myeloma, a further validation of the drug’s therapeutic potential in patients with this disease who have limited treatment options once they have relapsed,” said Gideon Bollag, PhD, chief scientific officer. Orphan Drug Designation is granted by the FDA to encourage the development of therapies for rare diseases, which are defined as those affecting fewer than 200,000 people in the U.S. The designation provides several benefits, including tax credits for clinical trial costs, a waiver of certain FDA fees, and eligibility for seven years of market exclusivity upon approval. Opna recently presented data at the American Society of Hematology (ASH) meeting in December 2024 showing that in human-derived multiple myeloma models, OPN-6602 suppresses tumor growth, while downregulating key MM driving genes. Synergistic effects were observed with OPN-6602 in combination with dexamethasone, pomalidomide and mezigdomide. OPN-6602’s distinct pharmacokinetic profile allows for continuous daily dosing that potentially results in a lower incidence of toxicities and improved efficacy. The Phase 1 study in patients with relapsed or refractory multiple myeloma (NCT06433947) is taking place at multiple sites in the U.S. Opna Bio expects to complete the single agent, dose-escalation phase of the trial in 2026. Further development of OPN-6602 in combination with other standard-of-care agents in multiple myeloma is planned. About Opna Bio Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X multifunctional RNA-binding protein (FMRP) and a diversified pipeline of promising oncology assets. The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. Opna’s lead clinical compounds include OPN-2853, a potentially best-in-class BET bromodomain inhibitor, being evaluated in patients with myelofibrosis in combination with ruxolitinib, and OPN-6602, a dual EP300/CBP inhibitor, currently being studied in a first-in-human Phase 1 clinical trial in patients with multiple myeloma. For more information, please visit opnabio.com .

Phase 1Orphan DrugASH

09 Dec 2024

·www.businesswire.com

Opna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis

SAN DIEGO--( BUSINESS WIRE )--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced interim data from its lead clinical program, OPN-2853, in patients with advanced myelofibrosis showing encouraging levels of spleen reduction, with minimal toxicities and adverse events. Preclinical data from a second program, OPN-6602, showed significant tumor regression in multiple myeloma models as a single agent and in combination with other therapeutics. The presentations took place this weekend at the American Society of Hematology (ASH) annual meeting, December 7-10, 2024, in San Diego. OPN-2853 Shows Spleen Reduction in Patients with Advanced Myelofibrosis OPN-2853, a small molecule bromodomain and extra-terminal motif (BET) inhibitor, is being evaluated in an ongoing Phase 1 investigator-led study in patients with advanced myelofibrosis who are no longer responding to ruxolitinib alone. Myelofibrosis is a type of blood cancer that causes fibrosis in the bone marrow, anemia and enlarged spleen, amongst other symptoms. The study is testing three dose levels of OPN-2853 (20 mg, 40 mg and 80 mg), given orally once daily, in combination with ruxolitinib. As of February 2024, the cut-off date, 16 patients had been enrolled at different dose levels, across multiple sites in the United Kingdom, coordinated by the Cancer Research UK (CRUK) Clinical Trials Unit at the University of Birmingham. In 12 evaluable patients, the median spleen size was reduced from baseline with spleens no longer palpable in 50% of evaluable patients. The combination dose has been well tolerated, and the majority of patients have completed eight cycles of combination treatment. “We are very encouraged by these data to date, which demonstrate that daily dosing of OPN-2853 in combination with ruxolitinib was well tolerated, and showed spleen reduction in patients with myelofibrosis who have very limited options once they have progressed,” said principal investigator Adam Mead, PhD, MRCP, FRCP, professor of hematology at the University of Oxford and CRUK senior cancer research fellow. “We are enthusiastic about the OPN-2853 and ruxolitinib combination and expect to have a recommended Phase 2 dose in early 2025.” Opna Bio is planning further clinical development with OPN-2853. OPN-6602 Combinations Demonstrate Complete Tumor Regression in Preclinical Multiple Myeloma Models OPN-6602, an oral, small molecule inhibitor of the E1A binding protein (EP300) and CREB-binding protein (CBP), is currently being tested in a Phase 1 trial in patients with multiple myeloma (MM) . MM is a type of blood cancer derived from malignant plasma cells in the bone marrow. In MM mouse xenograft models, OPN-6602 showed 71% tumor suppression as a single agent, and 100% tumor regression when combined with dexamethasone, pomalidomide or mezigdomide with a sustained duration of response. RNA sequencing of treated tumors showed that OPN-6602 downregulated key MM driver and signature genes, and has the potential to overcome resistance mechanisms to standard-of-care regimens. “We are very encouraged by the strength of the OPN-2853 clinical and OPN-6602 preclinical data, which highlights the potential of their unique pharmacokinetic profiles and validates our ‘safety by design’ approach. Both drug candidates have a high Cmax and short half-life, which allows for continuous daily dosing and effective target engagement with rapid clearance to mitigate toxicities,” said Gideon Bollag, PhD, co-founder and chief scientific officer of Opna Bio. “This confers a significant advantage to these drugs when used as single agents and a potentially synergistic effect when used in combination with other therapies.” About Opna Bio Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X multifunctional RNA-binding protein (FMRP) and a diversified pipeline of promising oncology assets. The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. Opna’s lead clinical compounds include OPN-2853, a potentially best-in-class BET bromodomain inhibitor, being evaluated in patients with myelofibrosis in combination with ruxolitinib, and OPN-6602, a dual EP300/CBP inhibitor, currently being studied in a first-in-human Phase 1 clinical trial in multiple myeloma patients. For more information, please visit opnabio.com .

Phase 1Clinical ResultASH

04 Dec 2024

·www.prnewswire.com

Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed Decision-Making | DelveInsight

A case study on how a leading pharma company in hematology turned to DelveInsight for long-term competitive intelligence support. DelveInsight provided an in-depth analysis of competitive activity in key hematological malignancies, helping the company stay ahead of the competition. LAS VEGAS, Dec. 4, 2024 /PRNewswire/ -- DelveInsight, a leader in healthcare competitive intelligence and consulting, released a case study on Competitive Intelligence in the Hematology Domain. A Europe-based client approached DelveInsight to evaluate a long-term partnership for insights supporting their clinical, commercial, and launch strategies for a novel oncology product targeting acute myeloid leukemia (AML), multiple myeloma, and acute lymphoblastic leukemia (ALL). The client sought detailed intelligence on competitive activity, class-wise market trends, launch estimates in countries of interest, and regulatory landscapes to inform their development and commercialization plans. An additional request for the segregation of mutation/protein expression-specific therapies was also taken into consideration. DelveInsight provided timely, in-depth analysis of the competitive landscape, emerging therapies, and regulatory situations across multiple countries. This enabled the client to make informed decisions on clinical development, market positioning, and commercialization, helping them stay ahead of the competition in the hematology space. With hundreds of thousands of new cases diagnosed annually, hematologic cancers, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and multiple myeloma, among others present a serious global health challenge while also opening doors for breakthroughs in targeted and personalized treatments. These cancers affect the blood, bone marrow, and lymphatic system, and often require aggressive therapies due to their rapid progression and complex nature. AML and ALL are particularly aggressive, with AML being one of the most common forms of leukemia in adults and ALL affecting both children and adults. Innovations in precision medicine and immunotherapy are transforming hematology, with CAR-T therapies showing promise for leukemias and CELMODs, like Iberdomide, emerging as potential successors to REVLIMID for multiple myeloma. Bristol Myers Squibb's collaboration with Karyopharm on mezigdomide highlights the growing focus on CELMODs. Additionally, FDA-approved therapies like CARVYKTI and TECVAYLI, along with ongoing advancements in bispecific antibodies and proteasome inhibitors, are reshaping the multiple myeloma treatment landscape, despite safety, cost, and manufacturing challenges. The market is rapidly evolving, with new therapies continually entering the pipeline. Several companies, including Bristol Myers Squibb, Celgene, Arcellx, Novartis, Regeneron Pharmaceuticals, Cartesian Therapeutics, Heidelberg Pharma, BeiGene, CARsgen Therapeutics, C4 Therapeutics, AbbVie (TeneoOne), Roche (Genentech), Pfizer, Agios Pharmaceuticals, Jazz Pharmaceuticals, Astellas Pharma, Novartis Oncology, Daiichi Sankyo, AstraZeneca/Astex Pharmaceuticals, Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Autolus Therapeutics, Cellectis, Wugen, Servier, Allogene, and Precision BioSciences, are currently advancing the therapeutic landscape for hematological disorders. As research and innovation progress, there is renewed hope for improving survival rates and enhancing the quality of life for those affected by these challenging diagnoses. DelveInsight's Methodology for Competitive Intelligence in the Hematology Domain helped the client by: Comparative Analyses: Evaluating competitor products to identify strengths, weaknesses, and market positioning, enabling the client to understand where their product stands relative to competitors along with identifying the patient segment with high unmet need KOL Insights: Gathering opinions from Key Opinion Leaders (KOLs) on clinical development strategies, client's product acceptability scenarios, data presentation, probable uptake of their asset,, providing valuable perspectives to refine the client's approach. Current Treatment Paradigms: Analyzing existing treatment approaches to identify market trends, gaps, and unmet needs, helping the client position their product effectively in the market. In-depth Competitive Benchmarking: Assessing competitors' commercial launch preparedness, patient awareness campaigns, and pricing strategies to inform the client's product's market entry and competitive strategy. Market Intelligence: Providing insights into competitors' marketing, sales, and patient engagement approaches, guiding the client's commercialization and go-to-market strategies. Clinical Development Trends: Evaluating clinical trial timelines and strategies, tracking phase shifts in terms of probability of their entry into the higher phase, and analyzing trial data to anticipate future market shifts and inform strategic decision-making. Pricing and Access Strategies: Analyzing competitor pricing models and access strategies, allowing the client to make informed decisions on pricing and reimbursement for their product. Request a proposal to see how DelveInsight's Competitive Intelligence services can support your long-term strategic insights. How DelveInsight's In-Depth Competitive Intelligence in Hematology Helped Clients Stay Ahead in the Market Periodic Competitive Inputs: Provided regular updates on competitor activities, keeping the client informed of market shifts. Enhanced Market Awareness: Delivered ongoing insights into competitor strategies, enabling quick adaptation to market changes. Short-Term Strategies: Developed actionable strategies for immediate response to competitor moves. Counter-Messaging Design: Assisted in crafting counter-messaging strategies to address competitor claims and strengthen brand positioning. Positioning Refinement: Helped refine product positioning to gain a competitive advantage. Promotional Strategy Support: Offered recommendations on promotional tactics to boost market presence and attract key audiences. Why Choose DelveInsight? DelveInsight offers tailored, comprehensive competitive intelligence to keep your hematology product developmental and commercial strategy a step ahead. With expertise in AML, Multiple Myeloma, ALL, and other hematology domains, we support your clinical, commercial, and launch strategies with insights that matter. What Sets Us Apart: Timely Intelligence: Consistent, real-time updates on competitor activities, clinical shifts, and regulatory changes, ensuring you're never caught off-guard. Expert Analysis: From comparative assessments to pricing benchmarks, we provide actionable data that sharpens your positioning. Strategic Edge: We don't just offer data—we deliver strategic recommendations for counter-messaging, promotional tactics, and market adaptation. Choosing DelveInsight means partnering with a team dedicated to turning competitive intelligence into growth and success for your business. Transform your business with our case study. Schedule a call with our DelveInsight Business Development expert today! Conference Coverage Services : DelveInsight's Conference Coverage Services offer a thorough analysis of outcomes from major events like ASH, EHA, AACR, ESMO, ASCO, and others. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Competitive Intelligence Services: DelveInsight's competitive intelligence services provide real-time, accurate insights across the pharmaceutical, life sciences, and medical diagnostics sectors, helping clients stay ahead in a dynamic market. With over 100 years of combined experience, our experts deliver actionable strategic insights, backed by robust research methodologies, to support critical business decisions and create a competitive advantage for our clients. Hematology Pipeline Assessment: Our hematology pipeline evaluation offers a comprehensive overview of cancer treatment options, clinical trials, and key areas within the hematological disorders field, all summarized in an accessible report format. The hematology-focused reports, available in our Report Store, provide in-depth insights into treatment strategies, mechanisms of action (MoAs), drug components, and launch plans for therapies in the late stages of development. This assessment enhances understanding of their launch timelines and strategic initiatives. R&D Analysis: Our skilled research and development analyst specializes in the complexities of hematology, offering essential insights and advice to clients aiming to advance in hematological research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each hematology drug in both pre-clinical and clinical stages. DelveInsight's comprehensive hematological reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyASH

100 Deals associated with Mezigdomide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 3	Belgium	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	Czechia	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	Finland	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	France	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	Ireland	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	Poland	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	Portugal	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	South Korea	Bristol Myers Squibb Co.	20 Sep 2022
Multiple Myeloma	Phase 3	Turkey	Bristol Myers Squibb Co.	20 Sep 2022
Refractory Multiple Myeloma	Phase 3	Belgium	Celgene Corp.	20 Sep 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Refractory Multiple Myeloma	-	MeziVd	btnxiplmcg(yflsmhkrgt) = The most common grade 3/4 TEAEs were neutropenia (35.7%), thrombocytopenia (21.4%), and infections (17.9%) with MeziVd; and neutropenia (44.4%) and infections (33.3%) with MeziKd betbpkdxkf (caxfutzfeb ) View more	-	09 Dec 2024
				MeziKd
SOHO2024	Not Applicable	Multiple Myeloma	-	Mezigdomide (MEZI) + Dexamethasone (DEX) + Bortezomib (BORT)	puiexrvqbo(ppwipnjcid) = zhbujuamrt gokezzblkv (betmgvdnlh ) View more	-	04 Sep 2024
				Mezigdomide (MEZI) + Dexamethasone (DEX) + Carfilzomib (CFZ)	puiexrvqbo(ppwipnjcid) = hegxygsghm gokezzblkv (betmgvdnlh ) View more
NCT03374085 (CC-92480-MM-001, ASCO2024) Manual	Phase 1/2	Relapse multiple myeloma \| Renal Insufficiency \| Refractory Multiple Myeloma	101	mezigdomide + dexamethasone	dimxrrofeq(ojoqokwogv) = zuxctpblca zzeyfesfrc (rjbmpqmfwt ) View more	Positive	24 May 2024
				mezigdomide + dexamethasone (No RI)	dimxrrofeq(ojoqokwogv) = sfrqgpkzfr zzeyfesfrc (rjbmpqmfwt ) View more
NCT05372354 (CA057-003, EHA2024) Manual	Phase 1/2	Multiple Myeloma PRC2 Loss of Function Mutation \| EZH2 Overexpression	10	MEZI+TAZ+DEX 0.3mg	crluwpkkna(sddqhjwcnm) = kwusqxahfb bqzqodhfvw (dnfdjgkaan ) View more	Positive	14 May 2024
ASH2023	Not Applicable	-	-	Mezigdomide	xdxiincley(tynwooxmte) = 98% reduction vtacixvjhl (slyjbywwek ) View more	-	09 Dec 2023
				DMSO controls
NCT03803644 \| NCT04211545 (Pubmed \| CPT Pharmacometrics Syst Pharmacol)	Phase 1	-	64	Mezigdomide	xqtxufcqdo(xqffiztbfl) = fttkzqmvnx eiybcrqyvq (gjrzcnfklm ) View more	Positive	01 Oct 2023
IMS2023	Not Applicable	Refractory Multiple Myeloma	17	Mezigdomide (MEZI)	mwsztqbhbb(nypawslwcp) = wmpvxwffdw ddprqnilwf (ddamwfwiig )	-	26 Sep 2023
NCT03989414 (CC-92480-MM-002, IMS2023)	Phase 1/2	Relapse multiple myeloma	-	MeziVd	rpuepnacww(zzkznpzinu) = aitvmqvttc ismcaxygax (rdxaiexadv ) View more	-	26 Sep 2023
				MeziVd-1.0mg	rpuepnacww(zzkznpzinu) = rycqwhikxg ismcaxygax (rdxaiexadv ) View more
NCT03374085 (CC-92480-MM-001, Pubmed)	Phase 1/2	Multiple Myeloma	101	Mezigdomide plus Dexamethasone	coenewzeui(pisemtwhit) = boidqtxxkd jckrvlrwpj (sqqxrmcktl, 31 - 51) View more	Positive	14 Sep 2023
SOHO2023	Not Applicable	Multiple Myeloma	-	MEZI 1 mg + DEX 40 mg	sciyertesx(ltnjwzloqc) = Ninety-two (91.1%) patients experienced grade 3–4 treatment-emergent adverse events (TEAEs). Most frequent hematologic grade 3–4 TEAEs were neutropenia (75.2%), anemia (35.6%), and thrombocytopenia (27.7%). Grade 3–4 infections occurred in 34.7% of patients; other grade 3–4 non-hematologic TEAEs were low. Due to TEAEs, 76 (75.2%) and 29 (28.7%) patients had MEZI dose interruptions and reductions, respectively. wasbpyswrp (iyetstfqgz )	-	01 Sep 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Mezigdomide

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation